Inflammation personifies the saying “too much of a good thing is bad.” Despite being one of the body’s first responders in case of infection or physical injury, inflammation also presents a significant risk to health. Acute inflammation is the body’s initial response to either infection or injury, and it is a crucial component of the body’s defense system. Chronic inflammation, on the other hand, happens when the body keeps sending inflammatory cells when there’s no present danger.
A wide variety of medical inflammations including Alzheimer’s disease, asthma, heart disease and cancer can be traced to chronic inflammation. This kind of inflammation usually results in symptoms such as pain in the abdomen, chest and joints, as well as fever, fatigue, headaches, swelling, mood disorders, and skin rashes. Current pharmaceutical medications for chronic inflammation can be quite effective at mitigating the condition, but they tend to cause adverse side effects after long-term use. Unsurprisingly, cannabis has emerged as a viable alternative due to its potent anti-inflammatory properties.
Studies have found that cannabis can function as an effective anti-inflammation agent because of how cannabinoids such as THC and CBD interact with the body. When you ingest cannabis, the cannabinoids interact with the endocannabinoid system (“ECS”), a part of the peripheral nervous system that regulates various functions, including immune response, sleep, appetite and mood. The ECS is filled with CB1 and CB2 receptors that normally respond to naturally produced endocannabinoids similar to the ones in cannabis. By interacting with this system, cannabis helps to inhibit chronic inflammation and mitigates its symptoms.
For instance, a study involving patients afflicted with Crohn’s disease found that 10 out of 11 participants enjoyed some relief from the condition after consuming marijuana. And since cannabis generally has no adverse side effects, the patients were able to avoid the adverse effects that usually result from long-term pharmaceutical drug use.
The controversial plant appears to be effective at easing the symptoms of cancer and cancer treatment, including nausea, insomnia and lack of appetite. HIV patients can also benefit from cannabis treatment as it can alleviate a variety of symptoms and significantly improve the quality of their lives.
Even with the limited research available, cannabis presents an effective alternative to pharmaceuticals for treating inflammatory conditions. Its side effects are inconveniences at best, and the substance can deliver a significant reduction in chronic inflammation. Consult your doctor if you would like to use cannabis to treat an inflammatory condition, and the doctor could also advise you about the best type of product for your needs, including the possibility of using a cannabis beverage made by one of the leading brands such as BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC).
NOTE TO INVESTORS: The latest news and updates relating to BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) are available in the company’s newsroom at http://cnw.fm/BVNNF
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
